Burns Kevin A, Ayoub Albert E, Breunig Joshua J, Adhami Faisal, Weng Wei-Lan, Colbert Melissa C, Rakic Pasko, Kuan Chia-Yi
Divisions of Developmental Biology and Pediatric Neurology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
Cereb Cortex. 2007 Nov;17(11):2585-92. doi: 10.1093/cercor/bhl164. Epub 2007 Jan 27.
The standard method of detecting neurogenesis uses bromodeoxyuridine (BrdU) to label DNA synthesis followed by double labeling with neuronal markers. However, DNA synthesis may occur in events unrelated to neurogenesis including aneuploidy and abortive cell cycle reentry. Hence, it is important to confirm neurogenesis with methods other than BrdU incorporation. To this end, we have generated transgenic nestin-CreER mice that express tamoxifen-inducible Cre recombinase under the control of a nestin enhancer. When crossed with a ubiquitous Enhanced Green Fluorescent Protein (EGFP)-Cre-reporter line, the bitransgenic animals can reveal the nestin-positive progenitors and their progeny with EGFP after tamoxifen induction. This system has many applications including visualization of embryonic neural progenitors, detection of postnatally transformed radial glial cells, and labeling adult neural progenitors in the subventricular zone (SVZ). To examine the contribution of SVZ progenitors to cell replacement after stroke, tamoxifen-induced mice were challenged with focal ischemia or combined ischemia-hypoxia followed by BrdU injection. This analysis revealed only very few EGFP-positive cells outside the SVZ after focal ischemia but robust DNA synthesis by hippocampal neurons without immediate cell death following ischemia-hypoxia. These results suggest that the nestin-CreER system is a useful tool for detecting embryonic and adult neurogensis. They also confirm the existence of nonproliferative DNA synthesis by old neurons after experimental brain injury.
检测神经发生的标准方法是使用溴脱氧尿苷(BrdU)标记DNA合成,随后用神经元标志物进行双重标记。然而,DNA合成可能发生在与神经发生无关的事件中,包括非整倍体和细胞周期的异常重新进入。因此,用除BrdU掺入之外的方法来确认神经发生很重要。为此,我们构建了转基因巢蛋白-CreER小鼠,其在巢蛋白增强子的控制下表达他莫昔芬诱导型Cre重组酶。当与普遍存在的增强型绿色荧光蛋白(EGFP)-Cre报告基因系杂交时,双转基因动物在他莫昔芬诱导后可用EGFP显示巢蛋白阳性祖细胞及其后代。该系统有许多应用,包括胚胎神经祖细胞的可视化、出生后转化的放射状胶质细胞的检测以及脑室下区(SVZ)成年神经祖细胞的标记。为了研究SVZ祖细胞对中风后细胞替代的贡献,对他莫昔芬诱导的小鼠进行局灶性缺血或联合缺血-缺氧攻击,随后注射BrdU。该分析显示,局灶性缺血后SVZ外只有极少数EGFP阳性细胞,但海马神经元在缺血-缺氧后有强烈的DNA合成且无立即细胞死亡。这些结果表明,巢蛋白-CreER系统是检测胚胎和成年神经发生的有用工具。它们还证实了实验性脑损伤后老龄神经元存在非增殖性DNA合成。